Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ABVC

ABVC - ABVC Biopharma Stock Price, Fair Value and News

0.83USD-0.06 (-6.74%)Market Closed

Market Summary

ABVC
USD0.83-0.06
Market Closed
-6.74%

ABVC Stock Price

View Fullscreen

ABVC RSI Chart

ABVC Valuation

Market Cap

9.0M

Price/Earnings (Trailing)

-0.71

Price/Sales (Trailing)

65.5

EV/EBITDA

-0.94

Price/Free Cashflow

-2.8

ABVC Price/Sales (Trailing)

ABVC Profitability

Operating Margin

-58.81%

EBT Margin

-8356.67%

Return on Equity

-162.02%

Return on Assets

-87.31%

Free Cashflow Yield

-35.65%

ABVC Fundamentals

ABVC Revenue

Revenue (TTM)

152.4K

Rev. Growth (Yr)

-99.63%

Rev. Growth (Qtr)

-86.37%

ABVC Earnings

Earnings (TTM)

-12.6M

Earnings Growth (Yr)

-115.66%

Earnings Growth (Qtr)

-26.42%

Breaking Down ABVC Revenue

Last 7 days

5.1%

Last 30 days

15.3%

Last 90 days

-16.2%

Trailing 12 Months

-78.2%

How does ABVC drawdown profile look like?

ABVC Financial Health

Current Ratio

0.27

ABVC Investor Care

Shares Dilution (1Y)

228.04%

Diluted EPS (TTM)

-2.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20231.1M765.6K739.3K152.4K
2022000969.8K
20210000
2020568.3K000
2019470.0K547.3K624.5K701.7K
20180238.3K315.6K392.8K
201771.1K161.1K00
201600073.4K
20153.0K2.3K3.4K0
201326.9K7.8K7.8K0
20120024.9K29.9K
20110000
201000434.1K0

Which funds bought or sold ABVC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
CITADEL ADVISORS LLC
sold off
-100
-31,503
-
-%
May 15, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
335
2,631
3,301
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
new
-
5,816
5,816
-%
May 14, 2024
Spotlight Asset Group, Inc.
unchanged
-
27.00
131
-%
May 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
added
12.94
6,224
28,820
-%
May 13, 2024
RENAISSANCE TECHNOLOGIES LLC
sold off
-100
-42,000
-
-%
May 10, 2024
VANGUARD GROUP INC
added
72.3
29,894
61,501
-%
May 10, 2024
WELLS FARGO & COMPANY/MN
added
140
40.00
63.00
-%
May 02, 2024
CHASE INVESTMENT COUNSEL CORP
new
-
233,000
233,000
0.09%

1–10 of 11

Are Funds Buying or Selling ABVC?

Are funds buying ABVC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABVC
No. of Funds

Unveiling ABVC Biopharma's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
lind global fund ii lp
9.9%
770,000
SC 13G/A
Aug 07, 2023
lind global fund ii lp
9.9%
385,000
SC 13G
Jul 12, 2022
jiang shuling
24.5%
7,908,805
SC 13D

Recent SEC filings of ABVC Biopharma

View All Filings
Date Filed Form Type Document
Jul 12, 2024
424B4
Prospectus Filed
Jul 12, 2024
8-K
Current Report
Jul 01, 2024
EFFECT
EFFECT
Jun 25, 2024
8-K/A
Current Report
Jun 24, 2024
8-K/A
Current Report
Jun 21, 2024
S-1
Initial Public Offering
May 28, 2024
D
D
May 24, 2024
8-K
Current Report
May 23, 2024
424B4
Prospectus Filed
May 23, 2024
8-K
Current Report

Peers (Alternatives to ABVC Biopharma)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

ABVC Biopharma News

Latest updates
Investing.com13 Jul 202402:28 am
Investing.com02 Jul 202407:00 am
Benzinga3 months ago
Pharmaceutical Technology8 months ago

ABVC Biopharma Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-100.0%-2,16515,8846,109128,272588,99442,269312,86025,66013,4301,20029,78858,37786,965115,55397,17078,78699,962197,733191,782212,242
Cost Of Revenue-99.8%277139,20629,61472,98160,236265,41110,7418,3671,8962,8023936461,2451,9028,6194,2363,9592,4892,79713,3521,499
Gross Profit100.7%928-137,041-13,730-66,87268,036323,58331,528304,49323,764-40,59598,60630,795261,90560,291106,934222,27774,82797,473194,936178,430210,743
Operating Expenses88.8%3,445,3181,824,5692,141,1432,126,9701,974,2203,456,5733,747,3692,351,3536,242,4856,406,5592,069,1602,066,3101,514,6504,910,9111,396,7001,416,2901,246,2041,221,2561,310,558667,238941,309
  S&GA Expenses-45.6%831,2571,526,6451,182,0931,386,7881,272,75267,4903,216,1461,592,8311,191,0781,766,8361,579,9961,231,6921,167,5951,080,8571,262,1991,277,1331,152,889937,5281,041,319571,669510,803
  R&D Expenses-4.3%69,06672,185141,310514,442334,9791,495,788305,483532,782359,404260,188263,424358,878121,315183,285134,501139,08292,790269,589269,23987,769421,956
EBITDA Margin-18.0%-62.94-53.35-12.83-14.34-10.15-15.67-31.17-28.14-28.17-19.31-17.58-17.99-18.09--------
Interest Expenses-37.9%684,6831,103,3011,218,624114,75256,663134,461126,53614,75818,213-24,36738,67782,671130,229116,67916,311140,525131,517107,474111,968132,686129,886
Income Taxes-100.0%-175,310-99981,695-962,8744,222-82,451-86,8671,011,279-75,667-59,564-51,024-86,405-44,735-48,644-40,568-27,25348,555-40,798-57,545
Earnings Before Taxes-26.2%-3,981,019-3,154,443-3,369,079-2,233,530-1,897,230-3,538,028-3,772,302-2,029,784-6,174,482-5,890,049-1,961,911-2,112,520-1,246,347-5,055,539-2,175,866-2,232,701-1,349,830-1,143,038-1,281,130-655,251-930,862
EBT Margin-19.6%-83.57-69.90-14.93-14.94-10.48-16.00-31.44-28.25-28.40-19.73-18.26-18.64-18.85--------
Net Income-26.4%-3,932,976-3,110,934-3,317,516-2,263,511-1,823,695-4,863,938-3,704,864-1,858,997-5,995,440-7,858,150-1,806,488-2,052,956-1,195,323-4,969,134-2,131,131-2,184,057-1,309,262-1,115,785-1,329,685-614,453-873,317
Net Income Margin-20.1%-82.82-68.99-16.60-16.53-11.42-16.93-34.17-30.83-31.17-22.72-17.64-18.21-18.44--------
Free Cashflow1.3%-473,161-479,460-1,359,014-899,916-1,497,722-461,158-518,061-3,451,387-3,087,477-2,524,616-2,216,025-1,444,004-1,413,074--------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.2%14,46014,49316,5929,32010,7359,58010,48113,78312,06713,69812,3558,94510,52611,6076,5296,4326,6656,9287,4057,1407,450
  Current Assets8.3%1,7941,6572,4942,1293,4802,9872,9039,7897,9887,6547,1113,6285,2056,1731,1781,6058028781,7081,2341,527
    Cash Equivalents-49.3%30.0060.001,12199.001,79285.001,9703,5993,4336,5654,4501,6573,3335,0011524061401601,052556997
  Inventory-------20.0022.0023.0026.0060.00--------258*521*
  Net PPE-0.3%7,9497,9697,954564572574567597599526528512505515506508505521514529548
Liabilities9.6%6,9736,3627,5309,6879,0006,3434,7874,6024,7054,8284,7658,4298,7978,9457,7217,8767,8377,0536,67510,28212,977
  Current Liabilities11.8%6,6345,9325,3635,7735,0755,5443,8943,6463,6643,6923,4394,3764,6664,8446,0467,5747,6556,8145,87810,10812,435
  Short Term Borrowings-4.3%861899853--1,894---1,640-----------
Shareholder's Equity-7.1%7,7928,3889,1001,3621,7353,0995,6939,1817,3618,8707,5905161,7292,662----730--
  Retained Earnings-6.0%-69,353-65,420-62,309-58,991-56,728-54,904-50,040-46,335-44,476-38,481-30,548-28,742-26,770-25,642-20,794-18,948-17,098-15,851-14,773-13,558-13,001
  Additional Paid-In Capital4.1%86,02982,63780,66268,07868,04867,93766,49466,24062,57958,11449,71641,00240,75240,75229,94928,22328,22328,18028,18018,68815,681
Accumulated Depreciation-0.4%3,3223,335-------------------
Shares Outstanding34.7%10,6987,9404,8233,3083,3083,2863,1203,1312,9682,5052,5042,4422,442--------
Minority Interest-18.7%-305-257-38.2612.0064.00138-225-153-65.4927.00-1,004-924-843-776-655-370-35.5826.0064.00179236
Float----5,200---18,852---16,488---73,262-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations1.3%-473-479-1,358-899-1,497-461-513-3,429-2,994-2,524-2,216-1,444-1,413-2,188-328-1,416-630-1,495-242-796-599
  Share Based Compensation1027.4%2,5452268182263661,8932262264,6924,3802264762263,14799975*525*-1676.008.009.00
Cashflow From Investing-100.0%-154-73.78---83.29-1,523-22.03-93.22427-810-140-281107-365---218*-14.10-3.17-17.80
Cashflow From Financing673.5%67687.001,657-31.592,207-253604--4,2535,817-11642.006,8694441,6456106047523581,374
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ABVC Income Statement

2024-03-31
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenues$ 1,205$ 128,272
Cost of revenues27760,236
Gross (loss) profit92868,036
Operating expenses  
Selling, general and administrative expenses831,2571,272,752
Research and development expenses69,066334,979
Stock-based compensation2,544,995366,489
Total operating expenses3,445,3181,974,220
Loss from operations(3,444,390)(1,906,184)
Other income (expense)  
Interest income4,04952,711
Interest expense(684,683)(56,663)
Operating sublease income22,100
Gain/(Loss) on foreign exchange changes113,520(12,261)
Other (expense) income30,4853,067
Total other income (expense)(536,629)8,954
Loss before income tax(3,981,019)(1,897,230)
Provision for (benefit from) income tax
Net loss(3,981,019)(1,897,230)
Net loss attributable to noncontrolling interests(48,043)(73,535)
Net loss attributed to ABVC and subsidiaries(3,932,976)(1,823,695)
Foreign currency translation adjustment(283,064)29,109
Comprehensive loss$ (4,216,040)$ (1,794,586)
Net loss per share:  
Basic (in Dollars per share)$ (0.4)$ (0.55)
Weighted average shares used in computing net loss per share of common stock(1):  
Basic (in Shares)[1]9,736,1503,307,577
[1]Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.

ABVC Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current Assets  
Cash and cash equivalents$ 30,489$ 60,155
Restricted cash628,513656,625
Accounts receivable, net1,5301,530
Short-term investments75,91679,312
Prepaid expense and other current assets159,602101,051
Total Current Assets1,794,4501,656,709
Property and equipment, net7,949,1507,969,278
Operating lease right-of-use assets708,023809,283
Long-term investments2,474,5142,527,740
Deferred tax assets, net
Prepaid expenses – non-current75,41678,789
Security deposits60,64462,442
Prepayment for long-term investments1,274,8421,274,842
Due from related parties – non-current, net123,363113,516
Total Assets14,460,40214,492,599
Current Liabilities  
Short-term bank loans860,750899,250
Accrued expenses and other current liabilities4,050,8453,696,380
Contract liabilities79,50079,500
Taxes payables108,110112,946
Operating lease liabilities – current portion389,870401,826
Convertible notes payable – third parties, net842,567569,456
Total Current Liabilities6,633,6145,932,490
Tenant security deposit21,68021,680
Operating lease liability – non-current portion318,153407,457
Total Liabilities6,973,4476,361,627
COMMITMENTS AND CONTINGENCIES
Equity  
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 authorized, 10,698,315 and 7,940,298 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively(1)[1]10,6987,940
Additional paid-in capital86,029,23782,636,966
Stock subscription receivable(225,740)(451,480)
Accumulated deficit(69,353,071)(65,420,095)
Accumulated other comprehensive income233,323516,387
Treasury stock(8,902,371)(8,901,668)
Total Stockholders’ equity7,792,0768,388,050
Noncontrolling interest(305,121)(257,078)
Total Equity7,486,9558,130,972
Total Liabilities and Equity14,460,40214,492,599
Related Party  
Current Assets  
Accounts receivable – related parties, net10,46310,463
Due from related parties – current887,937747,573
Due from related parties – non-current, net123,363113,516
Current Liabilities  
Due to related parties$ 301,972$ 173,132
[1]Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.
ABVC
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
 WEBSITEabvcpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES19

ABVC Biopharma Frequently Asked Questions


What is the ticker symbol for ABVC Biopharma? What does ABVC stand for in stocks?

ABVC is the stock ticker symbol of ABVC Biopharma. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ABVC Biopharma (ABVC)?

As of Fri Jul 19 2024, market cap of ABVC Biopharma is 9.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABVC stock?

You can check ABVC's fair value in chart for subscribers.

What is the fair value of ABVC stock?

You can check ABVC's fair value in chart for subscribers. The fair value of ABVC Biopharma is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ABVC Biopharma is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABVC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ABVC Biopharma a good stock to buy?

The fair value guage provides a quick view whether ABVC is over valued or under valued. Whether ABVC Biopharma is cheap or expensive depends on the assumptions which impact ABVC Biopharma's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABVC.

What is ABVC Biopharma's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, ABVC's PE ratio (Price to Earnings) is -0.71 and Price to Sales (PS) ratio is 65.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABVC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ABVC Biopharma's stock?

In the past 10 years, ABVC Biopharma has provided -0.564 (multiply by 100 for percentage) rate of return.